​

Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OVID Stock Forecast

Ovid Therapeutics (OVID) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $6.25, with a high of $8.00 and a low of $5.00. This represents a 163.71% increase from the last price of $2.37.

$1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $6.25 Low: $5 Last Closed Price: $2.37

OVID Stock Rating

Ovid Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

OVID Price Target Upside V Benchmarks

TypeNameUpside
StockOvid Therapeutics163.71%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts248
Avg Price Target$6.00$6.25$5.13
Last Closing Price$2.37$2.37$2.37
Upside/Downside153.16%163.71%116.46%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-10---10
Sep, 26-10---10
Aug, 26-10---10
Jul, 26-10---10
Jun, 26-10---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2026Wolfe Research$5.00$2.19128.31%110.97%
Oct 05, 2026Guggenheim$7.00$2.34199.15%195.36%
Sep 11, 2026Raghuram SelvarajuH.C. Wainwright$5.00$2.6390.11%110.97%
Sep 03, 2026Boobalan PachaiyappanRoth Capital$8.00$2.80185.71%237.55%
May 14, 2026Roth Capital$7.00$2.82148.23%195.36%
Apr 09, 2026H.C. Wainwright$4.00$2.8838.89%68.78%
Dec 11, 2025Boobalan PachaiyappanRoth Capital$3.00$1.6384.05%26.58%
Nov 24, 2025H.C. Wainwright$2.00$1.4042.86%-15.61%
Jul 02, 2024Raghuram SelvarajuH.C. Wainwright$3.00$0.86248.84%26.58%
May 20, 2024Thomas ShraderBTIG$11.00$3.14250.32%364.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2026Wolfe ResearchOutperforminitialise
Oct 09, 2026Cantor FitzgeraldOverweightinitialise
Oct 05, 2026GuggenheimBuyinitialise
Sep 11, 2026UBSBuyBuyhold
Sep 11, 2026H.C. WainwrightBuyBuyhold
Sep 03, 2026Roth CapitalBuyBuyhold
Jul 21, 2026B. RileyBuyBuyhold
May 14, 2026Roth CapitalBuyBuyhold
Apr 09, 2026H.C. WainwrightBuyBuyhold
Dec 11, 2025Roth CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-3 $-1 $1 $3 $5 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.78$-0.77$-0.74$-0.37$-0.23---
Avg Forecast$2.02$-0.75$-0.21$-0.47$-0.61$-0.34$-0.80$-0.80
High Forecast$6.56$0.14$0.14$-0.45$-0.15$0.47$-0.70$0.20
Low Forecast$-0.36$-2.52$-0.57$-0.48$-0.78$-0.78$-0.98$-2.77
Surprise %-11.88%2.67%252.38%-21.28%-62.30%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$208.38M$1.50M$392.00K$566.00K$7.25M---
Avg Forecast$208.39M$1.47M$8.79M$662.78K$4.62M$26.61M$4.03M$21.59M
High Forecast$569.19M$4.12M$9.54M$760.56K$13.29M$76.61M$11.59M$62.16M
Low Forecast$19.61M$124.51K$8.28M$532.39K$174.91K$1.01M$152.46K$817.87K
Surprise %-0.00%2.42%-95.54%-14.60%57.05%---

Net Income Forecast

$-200M $-60M $80M $220M $360M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$122.83M$-54.17M$-52.34M$-26.43M$-17.41M---
Avg Forecast$142.45M$-53.11M$-14.94M$-32.50M$-42.71M$-28.91M$-59.29M$-56.70M
High Forecast$463.05M$10.07M$10.19M$-32.00M$-10.69M$32.91M$-49.41M$14.22M
Low Forecast$-25.31M$-177.97M$-40.06M$-33.64M$-54.98M$-55.10M$-69.17M$-195.18M
Surprise %-13.77%2.00%250.44%-18.67%-59.22%---

OVID Forecast FAQ

Is Ovid Therapeutics stock a buy?

Ovid Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ovid Therapeutics is a favorable investment for most analysts.

What is Ovid Therapeutics's price target?

Ovid Therapeutics's price target, set by 14 Wall Street analysts, averages $6.25 over the next 12 months. The price target range spans from $5 at the low end to $8 at the high end, suggesting a potential 163.71% change from the previous closing price of $2.37.

How does Ovid Therapeutics stock forecast compare to its benchmarks?

Ovid Therapeutics's stock forecast shows a 163.71% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ovid Therapeutics over the past three months?

  • October 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ovid Therapeutics’s EPS forecast?

Ovid Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.34, marking a 47.83% increase from the reported $-0.23 in 2025. Estimates for the following years are $-0.8 in 2027, and $-0.8 in 2028.

What is Ovid Therapeutics’s revenue forecast?

Ovid Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $26.61M, reflecting a 266.94% increase from the reported $7.25M in 2025. The forecast for 2027 is $4.02M, and $21.59M for 2028.

What is Ovid Therapeutics’s net income forecast?

Ovid Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-28.905M, representing an 65.99% increase from the reported $-17.414M in 2025. Projections indicate $-59.288M in 2027, and $-56.7M in 2028.